PURPOSE: Retinal gene therapy trials are currently ongoing in a small number of inherited retinal disorders and this number is expected to rise significantly. The aim of this study was to analyze the psychological aspects of patients with RPE65 deficiency awaiting potential enrollment in gene therapy trials. METHODS: Five patients with genetically proven RPE65 deficiency took part in this study. They were asked to complete the German versions of (i) the Patient Health Questionnaire (PHQ-D), (ii) the National Eye Institute Visual Function Questionnaire (NEI-VFQ), (iii) the Shared Decision Making Questionnaire (PEF-FB-9), and (iv) the Autonomy Preference Index (API-Dm), and in addition they took part in qualitative interviews. RESULTS: The evaluations of the questionnaires and the interviews showed that the patients have quite high information needs and wish to take part in medical decisions. The perspective to participate in gene therapy trials does not seem to cause pronounced worries. Only the insecurity about if and when enrollment in a trial takes place may be burdensome. DISCUSSION: This study generated important data about the psychological situation of patients awaiting potential enrollment in clinical trials, which can be used to improve patient care in the increasing number of future gene therapy trials around the world.
PURPOSE: Retinal gene therapy trials are currently ongoing in a small number of inherited retinal disorders and this number is expected to rise significantly. The aim of this study was to analyze the psychological aspects of patients with RPE65 deficiency awaiting potential enrollment in gene therapy trials. METHODS: Five patients with genetically proven RPE65 deficiency took part in this study. They were asked to complete the German versions of (i) the Patient Health Questionnaire (PHQ-D), (ii) the National Eye Institute Visual Function Questionnaire (NEI-VFQ), (iii) the Shared Decision Making Questionnaire (PEF-FB-9), and (iv) the Autonomy Preference Index (API-Dm), and in addition they took part in qualitative interviews. RESULTS: The evaluations of the questionnaires and the interviews showed that the patients have quite high information needs and wish to take part in medical decisions. The perspective to participate in gene therapy trials does not seem to cause pronounced worries. Only the insecurity about if and when enrollment in a trial takes place may be burdensome. DISCUSSION: This study generated important data about the psychological situation of patients awaiting potential enrollment in clinical trials, which can be used to improve patient care in the increasing number of future gene therapy trials around the world.
Authors: Amy Turriff; Delphine Blain; Morgan Similuk; Barbara Biesecker; Henry Wiley; Catherine Cukras; Paul A Sieving Journal: Am J Ophthalmol Date: 2019-03-16 Impact factor: 5.258
Authors: Heather G Mack; Alexis Ceecee Britten-Jones; Myra B McGuinness; Fred K Chen; John R Grigg; Robyn V Jamieson; Thomas L Edwards; John De Roach; Fleur O'Hare; Keith R Martin; Lauren N Ayton Journal: Gene Ther Date: 2022-10-02 Impact factor: 4.184
Authors: Olalekan Lee Aiyegbusi; Karen Macpherson; Lauren Elston; Susan Myles; Jennifer Washington; Nisha Sungum; Mark Briggs; Philip N Newsome; Melanie J Calvert Journal: Nat Commun Date: 2020-12-08 Impact factor: 14.919
Authors: Myra B McGuinness; Alexis Ceecee Britten-Jones; Lauren N Ayton; Robert P Finger; Fred K Chen; John Grigg; Heather G Mack Journal: Transl Vis Sci Technol Date: 2022-02-01 Impact factor: 3.283
Authors: Heather G Mack; Fred K Chen; John Grigg; Robyn Jamieson; John De Roach; Fleur O'Hare; Alexis Ceecee Britten-Jones; Myra McGuinness; Nicole Tindill; Lauren Ayton Journal: BMJ Open Date: 2021-06-22 Impact factor: 2.692